一个多切片注意力融合和多视图个性化融合轻量级网络用于阿尔茨海默病诊断
Qiongmin Zhang1, Ying Long2, Hongshun Cai2
1College of Computer Science and Engineering, Chongqing University of Technology, Chongqing, China. zqm@cqut.edu.cn.
BMC medical imaging
|September 28, 2024
概括
这项研究引入了用于阿尔茨海默病 (AD) 诊断的轻量级网络,提高了准确性,同时降低了计算成本. 这种新的融合方法提高了早期检测AD病变.
科学领域:
- 医疗成像医学成像
- 人工智能的人工智能
- 神经学 神经学
背景情况:
- 阿尔茨海默氏病 (AD) 诊断面临3DMRI分析的挑战,原因是高计算需求和2D切片分析的潜在信息丢失.
- 现有的方法在自动化AD检测中努力平衡准确性和效率.
研究的目的:
- 开发一个轻量级的网络,用于自动化的阿尔茨海默病诊断,它在计算上是高效和准确的.
- 为了克服3D和2DMRI分析在AD检测中的局限性.
主要方法:
- 一个多分支的轻量级脊柱从斜,轴向和冠状MRI视图中提取特征.
- 一个多切片注意力融合模块集成了全球和本地频道注意力,以实现一致的切片分类.
- 一个多视图个性化融合模块将权重分配给不同的视图,以标签一致性损失为指导.
主要成果:
- 拟议的网络在对阿尔茨海默病 (AD) 与认知正常 (CN),AD与AD的分类方面取得了高准确性. 轻度认知障碍 (MCI) 和MCI与CN (分别为95.63%,86.88%,85.00%).
- 该方法显著降低了模型参数 (3.75M) 和FLOP (4.45G),表明了高效率.
- 与现有方法相比,在三个任务中,准确度提高了10.5%至14%.
结论:
- 拟议的轻量级网络为自动化AD诊断提供了卓越的资源利用和准确性.
- 它有效地识别出微妙的早期AD病变,有助于及时干预和治疗.
- 该方法为神经退行性疾病检测中的临床应用提供了至关重要的技术支持.
相关概念视频
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170


